Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 528 results for meta analysis

  1. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  2. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.

  3. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  4. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

  5. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.

  6. Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)

    Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.

  7. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  8. Stent-graft placement in abdominal aortic aneurysm (HTG106)

    Evidence-based recommendations on stent-graft placement in abdominal aortic aneurysm. This involves patching the weakened section of the aorta with a graft mounted on a stent.

  9. Anakinra for treating Still's disease (TA685)

    Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.

  10. Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)

    Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.

  11. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  12. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)

    Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.

  13. Open prenatal repair for open neural tube defects in the fetus (HTG537)

    Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus. This involves open surgery through the woman’s abdomen to close the gap in the baby’s spine.

  14. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

  15. Biopatch for venous or arterial catheter sites (MIB117)

    NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .